Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.

Anne Wojcicki, co-founder and former CEO of 23andMe, is set to regain control of the DNA-testing company after a nonprofit ...

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer protections ultimately led the board’s special committee to select it as ...

Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, ...

After a brief court dispute, 23andMe and all its assets are up for auction once again. The second time around, former CEO Amy ...

Anne Wojcicki's winning bid to reclaim control of 23andMe doesn't necessarily end the fight over what happens to the DNA of ...

Bankrupt genetic analysis company 23andMe will hold a second auction for its cache of DNA data with an opening bid of $305 ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...